This cluster is noise. The post-earnings window and strong fundamentals (raised guidance, Sephience momentum) continue to support PTCT. Monitor if larger C-suite sales emerge in the next 30 days, but this filing alone carries no bearish conviction.
Price Chart
Executive Summary
Two insiders at PTC Therapeutics sold a combined $220K of stock shortly after a strong Q1 earnings beat and raised guidance. CEO Matthew Klein's sale is a routine tax-withholding grant (12,500 shares awarded, none sold), while General Counsel Mark Boulding exercised options and sold a portion of the resulting shares. The total dollar value is only ~0.004% of market cap—immaterial and likely driven by standard post-earnings window openings and tax-planning, not a bearish signal.
Key Financial Metrics
Key Facts
- CEO Matthew Klein: 12,500 shares granted via award ($0) on May 13; then sold 679 shares at $73.06 ($50K) on May 14—a small tax-coverage disposition.
- General Counsel Mark Boulding: exercised 5,624 options (2,812 at $0, 2,812 at $25.69) on May 15; sold 2,356 shares ($170K) open-market.
- Total insider sales value ~$220K, representing ~0.004% of PTCT's $5.8B market cap.
- Just 12 days prior, PTCT reported Q1 2026 product revenue of $226M (up 47% YoY) and raised full-year product revenue guidance to $750-$850M.
- The insider cluster occurred after a strong earnings report and within an open trading window—consistent with routine post-earnings option exercises and tax sales.
Financial Impact
Insider sales of ~$220K — negligible relative to $5.8B market cap
Risk Factors
- Translarna and Emflaza revenue continue to decline due to generic erosion and regulatory headwinds.
- Any future insider sales above ~$2M (0.03% of market cap) would be more notable, especially if from CEO or CFO.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTCT-1779225646329 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Insider Cluster | $69.82 $65.26 | ▼ −6.53% | ▼ −6.00% | $63.46 (−9.11%) |
Jul 16, 2026 11w ago | Press Release | $78.52 $71.97 | ▲ +8.34% | ▲ +11.96% | $63.46 (+19.18%) |
Jul 16, 2026 11w ago | Insider Cluster | $78.52 $71.97 | ▼ −8.34% | ▼ −11.96% | $63.46 (−19.18%) |
Jul 13, 2026 11w ago | Insider Cluster | $81.33 $74.63 | ▼ −8.24% | ▼ −11.42% | $63.46 (−21.97%) |
Jul 8, 2026 12w ago | Insider Cluster | $88.57 $69.21 | ▼ −21.86% | ▼ −25.13% | $63.46 (−28.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $81.57 $76.82 | ▼ −5.82% | ▼ −5.54% | $63.46 (−22.20%) |
Jun 16, 2026 15w ago | 8-K | $73.27 $78.06 | ▲ +6.54% | ▲ +6.34% | $63.46 (−13.39%) |
Jun 9, 2026 16w ago | 8-K | $73.35 $89.55 | ▲ +22.09% | ▲ +18.46% | $63.46 (−13.48%) |
May 19, 2026 19w ago | Insider Cluster | $71.02 $78.98 | ▲ +11.21% | ▲ +10.47% | $63.46 (−10.64%) |
May 15, 2026 19w ago | Insider Cluster | $70.15 $73.27 | ▲ +4.45% | ▲ +2.87% | $63.46 (−9.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access